Peptilogics is an early-stage biotechnology company utilizing an innovative platform technology which enables us to rapidly and effectively develop novel peptide therapeutics, with a focus on antibiotics. Our pipeline includes a novel class of engineered Cationic Antimicrobial Peptides (eCAPs). Our compounds in development demonstrate the potential for powerful broad spectrum activity against the most dangerous drug-resistant bacteria, with minimal risk of generating drug resistance due to the unique mechanism of action. At Peptilogics, we are dedicated to being at the center of the solution to the growing global epidemic of multidrug-resistant bacterial infections, and to improving options for healthcare practitioners and patients across a multitude of indications.